Craig C. Hopkinson - 22 Feb 2023 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
22 Feb 2023
Net transactions value
-$148,431
Form type
4
Filing time
24 Feb 2023, 19:23:13 UTC
Previous filing
22 Feb 2023
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +12,038 +24% 61,904 22 Feb 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability $148,431 -5,345 -8.6% $27.77 56,559 22 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -12,038 -33% 24,076 22 Feb 2023 Ordinary Shares 12,038 Direct F1, F2
transaction ALKS Employee Stock Option (Right to Buy) Award $0 +120,615 $0.000000 120,615 23 Feb 2023 Ordinary Shares 120,615 $27.36 Direct F3
transaction ALKS Restricted Stock Unit Award Award $0 +30,154 $0.000000 30,154 23 Feb 2023 Ordinary Shares 30,154 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.
F3 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.